EMA fast tracks review of a medicine for metastatic pancreatic cancer
EMA’s human medicines committee (CHMP) has started a phased review of data on daraxonrasib, a medicine intended for the treatment of metastatic pancreatic cancer. A phased…
EMA’s human medicines committee (CHMP) has started a phased review of data on daraxonrasib, a medicine intended for the treatment of metastatic pancreatic cancer. A phased…
Read the full article at the source
Need oncology in Europe?
Browse verified clinics with transparent pricing and real reviews across 30+ countries.
Source.
European Medicines Agency — European Medicines Agency, CC BY 4.0
Medical disclaimer.
Articles are general information aggregated from third-party medical sources. They are NOT a substitute for in-person diagnosis or treatment. For personal medical guidance, consult a verified clinician or call your local emergency line (112 in the EU).